{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:22Z","timestamp":1795141102747,"version":"4.10.3"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate clinical factors that lead to \u226515-letter visual acuity loss following plaque radiotherapy of posterior uveal melanoma (PUM) in the pre\u2013anti-vascular endothelial growth factor (anti-VEGF) era.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors reviewed data on 4,000 consecutive patients with plaque-irradiated PUM managed between May 1976 and November 2008 to identify parameters predictive of \u226515-letter vision loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data included median patient age (60 years), diabetes mellitus (11%), median tumor diameter (11.0 mm) and thickness (4.5 mm), and median distance to optic disk (4.0 mm) and foveola (3.0 mm). Kaplan\u2013Meier analyses revealed \u226515-letter loss at 1 versus 3 versus 5 versus 10 years in 30% versus 60% versus 73% versus 82% of patients. Multivariate analyses revealed factors predictive of \u226515-letter loss included greater tumor thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01, hazard ratio [HR] 1.14), shorter distance to foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01, HR 0.93), greater radiation dose to foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01, HR 1.01) and lens (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01, HR 1.01), and presence of diabetes mellitus (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01, HR 1.11). For small PUM, multivariate risk factors included older age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), diabetes mellitus (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), and shorter distance to foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.02); for medium PUM, risk factors included greater tumor thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), shorter distance to foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), and less (but shorter) radiation dose to foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01); for large PUM, risk factors included greater tumor thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the pre\u2013anti-VEGF days, following treatment of PUM with plaque radiotherapy, clinical and treatment factors predictive of \u226515-letter visual acuity loss included greater tumor thickness, shorter distance to foveola, greater radiation dose to foveola and lens, and presence of diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004887","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:23:25Z","timestamp":1779200605000},"page":"1478-1485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["PLAQUE RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA IN 4,000 EYES"],"prefix":"10.1097","volume":"46","author":[{"given":"Carol L.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayet","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salaam","family":"Botros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranali","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taweevat","family":"Attaseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.oret.2025.09.003","article-title":"Risk factors for 15-letter visual acuity loss from geographic atrophy progression over one year in the age-related eye disease study 2","volume":"10","author":"Vance","year":"2016","journal-title":"Ophthalmol Retina"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2005.02.007","article-title":"Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment","volume":"50","author":"Slakter","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1167\/iovs.07-1132","article-title":"Report from the NEI\/FDA ophthalmic clinical trial design and endpoints symposium","volume":"49","author":"Csaky","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"15326","DOI":"10.1038\/s41598-019-51769-7","article-title":"Association of vision-related quality of life with visual function in age-related macular degeneration","volume":"9","author":"Pondorfer","year":"2019","journal-title":"Sci Rep"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0161-6420(98)91911-X","article-title":"Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time: the Beaver Dam Eye Study","volume":"105","author":"Klein","year":"1998","journal-title":"Ophthalmology"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41433-024-03520-4","article-title":"Edridge Green Lecture 2022\u2013Demystifying clinical trials and regulatory approvals in drug development","volume":"39","author":"Chong","year":"2025","journal-title":"Eye (Lond)"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","article-title":"Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. Visual acuity after 3 years. (COMS Report No. 16)","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.oret.2023.10.009","article-title":"Globe salvage and vision preservation by neoadjuvant darovasertib and crizotinib in uveal melanoma","volume":"8","author":"Hiong","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R12-20261120","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-025-01829-1","article-title":"Rewriting diabetes therapy: how incretin modulation is transforming cardiovascular and renal outcomes","author":"Miramontes-Gonz\u00e1lez","year":"2026","journal-title":"Diabetes Ther"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4103\/0301-4738.27087","article-title":"Snellen chart may be preferable over early treatment diabetic retinopathy study charts for rapid visual acuity assessment","volume":"54","author":"Tewari","year":"2006","journal-title":"Indian J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:16Z","timestamp":1795140016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004887"}},"subtitle":["Risk Factors for \u226515-Letter Visual Acuity Loss in the Pre\u2013Anti-VEGF Era"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004887","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}